Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Public Joint-Stock Company "Human Stem Cells Institute" (ISKJ.ME)
Moscow, RU
Public Joint-Stock Company "Human Stem Cells Institute," identified by the symbol ISKJ.ME, operates primarily as a biotechnology enterprise within Russia. The company focuses on pharmaceutical innovation, encompassing research, development, and the commercialization of its proprietary offerings in various therapeutic areas. These include regenerative medicine, bio-insurance, medical genetics (with a specific emphasis on reproductive applications), gene therapy, and biopharmaceutics. The institute manages Gemabank, a prominent family cord blood stem cell repository serving Russia and the Commonwealth of Independent States (CIS), and Reprobank, a facility for the personal cryopreservation of reproductive cells and tissues, which also facilitates sperm and oocyte donations. Among its key products is Neovasculgen, a gene-therapy medication for treating peripheral arterial disease, including critical limb ischemia. It also offers SPRS-therapy, a customized diagnostic and treatment approach designed for repairing skin damage. Furthermore, the company operates GENETICO, a specialized medical genetics center and molecular diagnostic laboratory. GENETICO delivers extensive genetic analysis and counseling services aimed at the early identification, prediction, and preventative management of genetic disorders, particularly those affecting the reproductive system. Its services extend to preimplantation genetic diagnostics and screening, involving the examination of developing embryos for hereditary monogenic conditions and chromosomal irregularities during in vitro fertilization cycles. The company additionally provides non-invasive prenatal testing to detect fetal chromosome abnormalities and is actively developing Gemacell, an investigational cell-based therapy targeting myocardial infarction. Beyond these, the firm supplies diagnostic services to uncover genetic predispositions to oncological diseases and distributes specialized equipment for cell processing. Established in Moscow, Russia, in 2003, Public Joint-Stock Company "Human Stem Cells Institute" functions as a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.55% | -17.08% | -18.46% | -30.25% | -32.66% | -30.76% | -40.81% | -55.44% | +25.17% | +102.15% | +279.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+12.8% ★ Q4'25: +126.0% (vs Q3'24)
-
EPS growth Biotechnology: +29.7%-44.4% Q4'25: -128.1% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-4.0% Q4'25: +1.1% (vs Q3'24)
-
EBIT margin Biotechnology: +0.0%+7.0% ★ Q4'25: +0.8% (vs Q3'24)
-
ROIC Biotechnology: -16.1%+8.7% ★ Q4'25: +1.4% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%-18.9% ★ Q4'25: +0.2% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.68× Q4'25: 2.85× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-30 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-29 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-24 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-23 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-17 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-16 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-03 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-02 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-26 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-25 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-19 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-18 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Artur Alexandrovich Isaev | Founder, Chairman & Member of Scientific Advisory Board | — | — |
| Blokhina Svetlana Viktorovna | Head of Corporate Department & Chairman of Audit Commission | — | female |
| Bulanova Galina Igorevna | Financial Director | — | — |
| Deev Roman Vadimovich | Chief Scientific Officer, Director & Member of Scientific Advisory Board | — | male |
| Dmitry Krasotkin | Investment Director | — | — |
| Oksana Peterson | Deputy Chief Accountant & Member of Audit Commission | — | — |
| Romanova Elena Anatolyevna | Director of Public Relations | — | female |
| Sergey Vladimirovich Masyuk | General Director | — | male |
| Zorin Vadim Leonidovich | Head of Regenerative Medicine Department & Member of Scientific Advisory Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ISKJ.ME
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
